Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
Author
Tefferi, Ayalew; Mudireddy, Mythri; Mannelli, Francesco; Begna, Kebede H.; Patnaik, Mrinal M.; Hanson, Curtis A.; Ketterling, Rhett P.; Gangat, Naseema; Yogarajah, Meera; De Stefano, Valerio; Passamont, Francesco; Rosti, Vittorio; Finazzi, Maria Chiara; Rambaldi, Alessandro; Bosi, Alberto; Guglielmelli, Paola; Pardanani, Animesh; Vannucchi, Alessandro M.
Abstract
A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from the
Mayo Clinic and 162 from Italy. Median survival was 3.6 months, with no improvement over the last 15 years. Multivariable
analysis performed on the Mayo cohort identified high risk karyotype, platelet count < 100 × 109
/L, age > 65 years and
transfusion need as independent risk factors for survival. Also in the Mayo cohort, intensive chemotherapy resulted in complete
remission (CR) or CR with incomplete count recovery (CRi) rates of 35 and 24%, respectively; treatment-specified 3-year/5-year
survival rates were 32/10% for patients receiving allogeneic stem cell transplant (AlloSCT) (n = 24), 19/13% for patients
achieving CR/CRi but were not transplanted (n = 24), and 1/1% in the absence of both AlloSCT and CR/CRi (n = 200) (p <
0.01). The survival impact of AlloSCT (HR 0.2, 95% CI 0.1–0.3), CR/CRi without AlloSCT (HR 0.3, 95% CI 0.2–0.5), high risk
karyotype (HR 1.6, 95% CI 1.1–2.2) and platelet count < 100 × 109
/L (HR 1.6, 95% CI 1.1–2.2) were confirmed to be interindependent. Similar observations were made in the Italian cohort. The current study identifies the setting for improved short-term
survival in MPN-BP, but also highlights the limited value of current therapy, including AlloSCT, in securing long-term survival.
Date
2018-02-02
Citation:
APA:
Tefferi, Ayalew, & Mudireddy, Mythri, & Mannelli, Francesco, & Begna, Kebede H., & Patnaik, Mrinal M., & Hanson, Curtis A., & Ketterling, Rhett P., & Gangat, Naseema, & Yogarajah, Meera, & De Stefano, Valerio, & Passamont, Francesco, & Rosti, Vittorio, & Finazzi, Maria Chiara, & Rambaldi, Alessandro, & Bosi, Alberto, & Guglielmelli, Paola, & Pardanani, Animesh, & Vannucchi, Alessandro M.. (February 2018).
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.
,
(),
-
. Retrieved from
http://hdl.handle.net/10342/8369
MLA:
Tefferi, Ayalew, and Mudireddy, Mythri, and Mannelli, Francesco, and Begna, Kebede H., and Patnaik, Mrinal M., and Hanson, Curtis A., and Ketterling, Rhett P., and Gangat, Naseema, and Yogarajah, Meera, and De Stefano, Valerio, and Passamont, Francesco, and Rosti, Vittorio, and Finazzi, Maria Chiara, and Rambaldi, Alessandro, and Bosi, Alberto, and Guglielmelli, Paola, and Pardanani, Animesh, and Vannucchi, Alessandro M..
"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts". .
. (),
February 2018.
May 29, 2023.
http://hdl.handle.net/10342/8369.
Chicago:
Tefferi, Ayalew and Mudireddy, Mythri and Mannelli, Francesco and Begna, Kebede H. and Patnaik, Mrinal M. and Hanson, Curtis A. and Ketterling, Rhett P. and Gangat, Naseema and Yogarajah, Meera and De Stefano, Valerio and Passamont, Francesco and Rosti, Vittorio and Finazzi, Maria Chiara and Rambaldi, Alessandro and Bosi, Alberto and Guglielmelli, Paola and Pardanani, Animesh and Vannucchi, Alessandro M.,
"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts," , no.
(February 2018),
http://hdl.handle.net/10342/8369 (accessed
May 29, 2023).
AMA:
Tefferi, Ayalew, Mudireddy, Mythri, Mannelli, Francesco, Begna, Kebede H., Patnaik, Mrinal M., Hanson, Curtis A., Ketterling, Rhett P., Gangat, Naseema, Yogarajah, Meera, De Stefano, Valerio, Passamont, Francesco, Rosti, Vittorio, Finazzi, Maria Chiara, Rambaldi, Alessandro, Bosi, Alberto, Guglielmelli, Paola, Pardanani, Animesh, Vannucchi, Alessandro M..
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. .
February 2018;
():
.
http://hdl.handle.net/10342/8369. Accessed
May 29, 2023.
Collections